natgillin/translations-raw huggingface dataset:
Among the subjects who received placebo during the double-blind period, the proportion of subjects with HBV DNA < 400 copies/mL rose sharply after they began treatment with open-label TDF (PLB-TDF group): 74.1% (40/54) of subjects in the
Med bolniki, ki so v dvojno slepem obdobju prejemali placebo, je delež bolnikov s koncentracijo HBV DNA < 400 kopij/ml po začetku odprtega zdravljenja z TDF (skupina PLB–TDF) strmo narasel: v 192. tednu je 74,1% (40/54) bolnikov v skupini PLB–TDF imelo koncentracijo
Among the women who received ellaOne in the phase III studies, only 0.4% reported heavy intermenstrual bleeding.
Od vseh žensk, ki so prejemale zdravilo ellaOne v študiji III. faze, jih je le (0,4 %) poročalo o močni krvavitvi v času med dvema menstruacijama.
Among them, sequence data from paired baseline and on treatment HBV isolates were available for 2 of 4 patients.
Med njimi so podatki o zaporedju izolatov uparjenih izhodiščnih vrednosti in HBV zdravljenih bolnikih na voljo za 2 od 4 bolnikov.
Among them, the incidence of adrenal phaeochromocytomas was increased relative to control in males at all dose levels ( 3 mg/kg/day) and in females receiving 10 mg/kg/day and above.
Pojav nadledvičnega feokromocitoma je bil pogostejši v zvezi s kontrolo pri samcih pri vseh odmerkih ( 3 mg/kg/dan) in pri samicah, ki so prejemale 10 mg/kg/dan in več.
Among them, two patients experienced a clinically meaningful decline in estimated GFR which improved after discontinuation of tenofovir disoproxil fumarate.
Med njimi sta imela dva bolnika klinično pomembno zmanjšanje ocenjene GFR, ki se je po prekinitvi uporabe dizoproksiltenofovirijevega fumarata izboljšala.
Among these 10 HIV-1 isolates, the mutations that emerged were M184V/I (n = 9) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), and N155H (n = 2) in integrase.
Med temi 10 izolati HIV-1 so se pojavile mutacije M184V/I (n = 9) in K65R/N (n = 2) v RT ter T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) in N155H (n = 2) v integrazi.
Among these conditions are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML).
Med temi okužbami je nefropatija, povezana z virusom BK, in progresivna multifokalna levkoencefalopatija (PML), povezana z virusom JC.
Among these conditions are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML).
Med temi stanji sta tudi z virusom BK povezana nefropatija in z virusom JC povezana progresivna multifokalna levkoencefalopatija (PML).
Among these conditions are BK virus-associated nephropathy and JC virus-associated progressive multifocal leukoencephalopathy (PML).
Med temi boleznimi sta nefropatija, povezana z virusom BK, in progresivna multifokalna encefalopatija (PML - Progressive Multifocal Leukoencephalopathy), povezana z virusom JC.
Among these patients, 28% receiving vedolizumab every eight weeks, 27% receiving vedolizumab every four weeks, and 13% receiving placebo achieved clinical remission at Week 52.
Od teh bolnikov je bila klinična remisija v 52. tednu dosežena pri 28 % bolnikov, ki so vedolizumab prejemali na vsakih osem tednov, 27 % bolnikov, ki so vedolizumab prejemali na vsake štiri tedne, in 13 % bolnikov, ki so prejemali placebo.
Among these patients, 36 had chronic phase CML and 16 patients had either accelerated or blast phase CML.
Med temi bolniki jih je 36 imelo kronično mieloično levkemijo v kronični fazi, 16 bolnikov pa je bodisi v pospešeni bodisi v blastni fazi.
Among these patients, 37% receiving vedolizumab every eight weeks, 35% receiving vedolizumab every four weeks, and 5% receiving placebo achieved clinical remission at Week 52.
Od teh bolnikov je bila klinična remisija v 52. tednu dosežena pri 37 % bolnikov, ki so vedolizumab prejemali na vsakih osem tednov, 35 % bolnikov, ki so vedolizumab prejemali na vsake štiri tedne, in 5 % bolnikov, ki so prejemali placebo.
Among these patients, the median time to first event was 28 days (range, 1 to 658 days) and the median duration per event was 12 days (range, 1 to 502 days).
Pri teh bolnikih je bila mediana časa do prvega dogodka 28 dni (razpon 1 do 658 dni), mediana trajanja dogodka pa je bila 12 dni (razpon 1 do 502 dni).
Among these, 1,585 women were treated with CE 0.45 mg/bazedoxifene 20 mg and 1,241 received placebo.
Med njimi je 1.585 žensk prejemalo 0,45 mg CE /20 mg bazedoksifena, 1.241 žensk pa je prejemalo placebo.
among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
alergijskih simptomov alergije na hrano*, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4)
Among those patients treated with the ZALTRAP/FOLFIRI regimen developing grade 3-4 hypertension, 54% had onset during the first two cycles of treatment (see section 4.4).
Med tistimi prejemniki sheme ZALTRAP/FOLFIRI, ki se jim je razvila hipertenzija 3. do 4. stopnje, se je pri 54 % pojavila v prvih dveh ciklusih zdravljenja (glejte poglavje 4.4).
Amongst 1,166 patients treated with lenvatinib, 3 patients (0.3%) had a Grade 4 haemorrhage and 5 patients (0.4%) had a Grade 5 reaction including arterial haemorrhage, haemorrhagic stroke, intracranial tumour haemorrhage, haemoptysis and tumour haemorrhage.
Med 1166 bolniki, zdravljenimi z lenvatinibom, so imeli 3 bolniki (0,3 %) krvavitve stopnje 4, 5 bolnikov (0,4 %) pa je imelo neželeni učinek stopnje 5, vključno z arterijsko krvavitvijo, hemoragično možgansko kapjo, krvavitvijo v znotrajlobanskem tumorju, hemoptizo in krvavitvijo v tumorju.
Amongst 1,166 patients treated with lenvatinib, Grade 3 or greater haemorrhage was reported in 2% of patients, 3 patients (0.3%) had a Grade 4 haemorrhage and 5 patients (0.4%) had a Grade 5 reaction including arterial haemorrhage, haemorrhagic stroke, intracranial tumour haemorrhage, haemoptysis and tumour haemorrhage.
Med 1166 bolniki, zdravljenimi z lenvatinibom, so poročali o krvavitvi stopnje 3 ali višje stopnje pri 2 % bolnikov, 3 bolniki (0,3 %) so imeli krvavitve stopnje 4, 5 bolnikov (0,4 %) pa je imelo neželeni učinek stopnje 5, vključno z arterijsko krvavitvijo, hemoragično možgansko kapjo, krvavitvijo v znotrajlobanski tumor, hemoptizo in krvavitvijo v tumor.
Amongst 1,166 patients treated with lenvatinib, there were 4 cases (0.3%) of arterial thromboembolisms (2 cases of myocardial infarction and 2 cases of cerebrovascular accident) with a fatal outcome.
Med 1.166 bolniki, zdravljenimi z lenvatinibom, so bili 4 primeri (0,3 %) arterijskih trombembolij (2 primera miokardnega infarkta in 2 primera cerebrovaskularnega insulta) s smrtnim izidom.
Amongst 1,166 patients treated with lenvatinib, there were 4 cases (0.3%) of PRES (0.3% were Grade 3 or 4), all of which resolved after treatment and/or dose interruption, or permanent discontinuation.
Med 1.166 bolniki, zdravljenimi z lenvatinibom, so bili 4 primeri (0,3 %) PRES (0,3 % jih je bilo stopnje 3 ali 4), od katerih so vsi okrevali po zdravljenju in/ali prekinitvi odmerjanja ali trajni ukinitvi.
Amongst the 47 patients with an isolated Del (5q) cytogenetic abnormality and treated with lenalidomide 10 mg, 27 patients (57.4%) achieved red blood cell transfusion independence.
Med 47 bolniki z izolirano citogenetsko nepravilnostjo del(5q), zdravljenimi z lenalidomidom 10 mg, je 27 bolnikov (57,4 %) doseglo neodvisnost od transfuzij rdečih krvnih celic.
Amongst the most commonly reported adverse reactions were injection site reactions and fever.
Med najpogostejšimi neželenimi učinki so bile reakcije na mestu cepljenja in zvišana telesna temperatura.
Amongst the most serious and/or common adverse reactions reported in Herceptin usage (intravenous and subcutaneous formulations) to date are cardiac dysfunction, administration-related reactions, haematotoxicity (in particular neutropenia), infections and pulmonary adverse reactions.
Med najbolj resnimi in/ali pogostimi neželenimi učinki, o katerih so poročali pri uporabi zdravila Herceptin (intravenske in subkutane oblike), so motnje v delovanju srca, reakcije, povezane z aplikacijo, hematotoksičnost (še posebno nevtropenija), okužbe in pljučni zapleti.
Amongst the most serious and/or common adverse reactions reported in Herceptin usage (intravenous and subcutaneous formulations) to date are cardiac dysfunction, infusion-related reactions, haematotoxicity (in particular neutropenia), infections and pulmonary adverse reactions.
Med najbolj resnimi in/ali pogostimi neželenimi učinki, o katerih so do zdaj poročali pri uporabi zdravila Herceptin (intravenske in subkutane oblike), so motnje v delovanju srca, infuzijske reakcije, hematotoksičnost (še posebno nevtropenija), okužbe in pljučni neželeni učinki.
Amongst those who responded at Week 16 (n=144), the Pediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received Humira throughout the study.
Med bolniki, ki so se odzvali 16. teden (n = 144), so se odzivi »Pediatric ACR« 30/50/70/90 v odprti podaljšani fazi ohranili do 2 leti pri tistih, ki so ves čas študije dobivali zdravilo Humira.
Amongst those who responded at Week 16 (n=144), the Pediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received Humira throughout the study.
Med bolniki, ki so se odzvali 16. teden (n = 144), so se odzivi »Pediatric ACR« 30/50/70/90 v odprti podaljšani fazi ohranili do 6 let pri tistih, ki so ves čas študije dobivali zdravilo Humira.
Amorphous aluminium hydroxyphosphate sulphate is included in the vaccine as an adjuvant.
Amorfni aluminijev hidroksifosfat sulfat je v cepivo dodan kot adjuvans.
Amount of Benlysta
Količina zdravila Benlysta
Amount of calories you can eat per day
Ciljna vrednost kalorij
Amount of PegIntron to administer (µg)
Količina zdravila PegIntron za injiciranje (g)
amount of product per day (ml/day)
Količin zdravila na dan (ml/dan)
amount of product per day (ml/day)
Količina zdravila na dan (ml/dan)
Amount of ViraferonPeg to administer (µg)
Količina zdravila Viraferon Peg za uporabo (µg)
Amount of ViraferonPeg to administer (µg)
Količina zdravila ViraferonP eg za uporabo (µg)
Amount Set to Inject
Količina, nastavljena za injiciranje
Amount to be withdrawn
Količina za izvlek
Amount to be withdrawn
Količina za uporabo
Amount(s) to be administered and administration route
Odmerjanje in pot uporabe
Amounts to be administered and administration route
Odmerjanje in način uporabe
Amounts to be administered and administration route
Odmerjanje in pot uporabe
Amounts to be administered and administration route
Odmerjanje in pot uporabe Govedo
Amounts to be administered and administration route
Odmerjanje in pot uporabe Subkutano dajanje.
Amounts to be administered and administration route Cattle:
Odmerjanje in pot uporabe Goveda:
Amounts to be administered and administration route Cattle:
Odmerjanje in pot uporabe Govedo:
Amounts to be administered and administration route Chickens
Odmerjanje in pot uporabe Piščanci
Amounts to be administered and administration route Dogs:
Odmerjanje in pot uporabe Psi:
Amounts to be administered and administration route Dosage
Odmerjanje in način uporabe Odmerjanje:
Amounts to be administered and administration route Dosage schedule:
Odmerjanje in pot uporabe
Amounts to be administered and administration route In feed use for pigs:
Odmerjanje in pot uporabe Dajanje v krmni mešanici za prašiče:
Amounts to be administered and administration route Inspired Concentration:
Odmerjanje in pot uporabe Koncentracija v vdihanem zraku:
Amounts to be administered and administration route.
Odmerjanje in način uporabe
Amounts to be administered:
Odmerjanje:
amphetamine or amphetamine derivatives;
amfetamin ali derivate amfetamina;
Amphetamine Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected to increase concentrations of amphetamine and its derivatives.
Ritonavir, odmerjan kot protiretrovirusno zdravilo, verjetno zavira CYP2D6, zato je treba pričakovati, da zviša koncentracijo amfetamina in njegovih derivatov.
amphiphilic medicines used to treat heart arrhythmias (such as amiodarone), or statins used to treat high cholesterol
amfifilna zdravila, ki se uporabljajo za zdravljenje srčnih aritmij (na primer amiodaron), ali statini, ki se uporabljajo za zdravljenje zvišanega holesterola,
amphotericin or co-trimoxazole, to treat fungal and bacterial infections
amfotericin ali kotrimoksazol za zdravljenje bakterijskih in glivičnih okužb;
amphotericin or co-trimoxazole, to treat fungal and bacterial infections
amfotericin ali kotrimoksazol za zdravljenje glivičnih in bakterijskih okužb,
AMPLIFY STUDY
Študija AMPLIFY-EXT
AMPOULE
AMPULA
Ampoule
Nalepka (ampula)
ampoule (glass)
(steklo)
Ampoule (glass)
Ampula (steklena)
Ampoule (glass)
Ampula (steklo)
Ampoule coloured ring
Barvni obroč na ampuli
AMPOULE LABEL
AMPULA
AMPOULE LABEL FOR SOLVENT
NALEPKA NA AMPULI ZA VEHIKEL
AMPOULE LABEL: 0.5ml SOLVENT
NALEPKA NA AMPULI: 0,5 ml VEHIKLA
AMPOULE WITH 1 ML
AMPULA Z 1 ML
AMPOULE WITH 2 ML
AMPULA Z 2 ML
Ampoules are intended for single use only, any unused portions must be discarded.
Ampule so namenjene le za enkratno uporabo, vse neuporabljeno zdravilo morate zavreči.
Ampoules are packed in pouches, one pouch contains 8 ampoules which correspond with 4 days of treatment.
Ampule so pakirane v vrečice, ena vrečica vsebuje 8 ampul,, kar ustreza štirim dnevom zdravljenja.
Ampoules of 1,000, 2,000 or 4,000 doses
Ampula s 1000, 2000 ali 4000 odmerki
AMPOULES OR VIALS
AMPULE ALI VIALE
Amprenavir 1,200 mg BID AUC ↑90 % with 800 mg TID indinavir alone (see Table 1).
AUC amprenavirja 1200 mg BID ↑ 90 % s
Amprenavir 800 mg TID (nelfinavir 750 mg TID)
amprenavir 800 mg trikrat na dan
Amprenavir and ritonavir levels may increase on stopping St John’s wort.
Ob prenehanju jemanja pripravkov, ki vsebujejo šentjanževko se lahko vrednosti amprenavirja in ritonavirja zvišajo.
Amprenavir AUC ↓ 0.67 (0.55-0.80)
AUC amprenavirja↓ 0,67 (0,55-0,80)
Amprenavir AUC ↔ 0.89 (0.77-
AUC amprenavirja ↔ 0,89 (0,77
Amprenavir AUC ↔ Amprenavir Cmin ↑ 189 % Nelfinavir AUC ↔
AUC amprenavirja ↔ Cmin amprenavirja ↑ 189 % AUC nelfinavirja ↔
Amprenavir AUC ↔ Amprenavir Cmin ↑ 189 % Nelfinavir AUC ↔
Cmin amprenavirja ↑ 189 % AUC nelfinavirja ↔
Amprenavir AUC  0.89 (0.77-
AUC amprenavirja  0,89 (0,77
Amprenavir AUC  0.67 (0.55-0.80)
AUC amprenavirja 0,67 (0,55-0,80)
Amprenavir AUC: ↑ 90 %
AUC amprenavirja: ↑ 90
Amprenavir blocks an enzyme called protease, which is involved in the reproduction of HIV.
Amprenavir zavira encim, imenovan proteaza, ki sodeluje pri razmnoževanju virusa HIV.
Amprenavir Cmax ↓ 0.75 (0.63-0.89)
Cmax amprenavirja ↓ 0,75 (0,63-0,89)
Amprenavir Cmax ↓ 39% Amprenavir AUC ↓ 44% Amprenavir Cmin ↓ 55%
Cmax amprenavirja ↓ 39% AUC amprenavirja ↓ 44% Cmin amprenavirja ↓ 55
Amprenavir Cmax ↔ 0.97 (0.85-1.10)
Cmax amprenavirja ↔ 0,97 (0,85-1,10)
Amprenavir Cmax  0.97 (0.85-1.10)
Cmax amprenavirja  0,97 (0,85-1,10)
Amprenavir Cmax  0.75 (0.63-0.89)
Cmax amprenavirja  0,75 (0,63-0,89)
Amprenavir Cmin ↓ 0.65 (0.49-0.85)
Cmin amprenavirja ↓ 0,65 (0,49-0,85)
Amprenavir Cmin ↓ 0.81 (0.69-0.96)
Cmin amprenavirja ↓ 0,81 (0,69-0,96)
Amprenavir Cmin  0.65 (0.49-0.85)
Cmin amprenavirja  0,65 (0,49-0,85)
Amprenavir Cmin  0.81 (0.69-0.96)
Cmin amprenavirja  0,81 (0,69-0,96)
Amprenavir concentrations are
Raltegravir
Amprenavir has been authorised in the European Union (EU) since October 2000 as Agenerase.
Amprenavir je od oktobra 2000 v Evropski uniji (EU) odobren pod imenom Agenerase.
Amprenavir is 14 % less bioavailable from the Agenerase oral solution than from the capsules; therefore, Agenerase capsules and Agenerase oral solution are not interchangeable on a milligram per milligram basis (see section 5.2).
Biološka uporabnost amprenavirja v peroralni raztopini je za 14 % manjša kot v kapsulah, zato kapsule Agenerase in peroralna raztopina Agenerase niso zamenljive v enakih miligramskih odmerkih (glejte poglavje 5.2).
Amprenavir is primarily bound to the alpha–1-acid glycoprotein (AAG), but also to albumin.
Amprenavir se primarno veže na kisli glikoprotein alfa-1 (AAG), vendar tudi na albumin.
Amprenavir levels may increase on stopping St John’s wort.
Ob prenehanju jemanja pripravkov iz šentjanževke se lahko vrednosti amprenavirja zvišajo.
Amprenavir  expected
amprenavir  pričakovano
amprenavir.
amprenavirjem.
Amprenavir/ritonavir and
Lahko je potrebna
Amprenavir: AUC * Amprenavir: Cmin *
amprenavir: Cmax * amprenavir: AUC * amprenavir: Cmin 
Amprenavir: Cmax *
paroksetin: AUC  55
Amprenavir: Cmax *
paroksetin: Cmax  51% paroksetin: AUC  55
AMS may occur more frequently in association with high-dose (2 g/kg) IVIg treatment.
AMS se lahko pojavi pogosteje v povezavi z velikimi odmerki (2 g/kg) i.v. imunoglobulinov.
AMS may occur more frequently in association with high-dose (2 g/kg) IVIg treatment.
AMS se lahko pojavi pogosteje v povezavi z velikimi odmerki (2 g/kg) zdravil i.v.
amylase elevations1
povišane vrednosti amilaze1
Amylase increased
povečana raven amilaze
Amylase increased
povečana vrednost amilaze
Amylase increased
Zvišana raven amilaze
Amylase increased
zvišana vrednost amilaze
Amylase increased
zvišanje amilaze
Amylase increased
zvišanje ravni amilaze
amylase increased, blood bilirubin increased, hypercalcaemia
zvišana amilaza, zvišan bilirubin v krvi, hiperkalciemija
amylolytic activity:
amilolitična aktivnost:
amylolytic activity: not less than 7,800 units* proteolytic activity: not less than 650 units*
amilolitična aktivnost: ne manj kot 7.800 enot*, proteolitična aktivnost: ne manj kot 650 enot*.
Amyvid 1900 MBq/mL solution for injection Amyvid 800 MBq/mL solution for injection Florbetapir (18F)
Amyvid 1900 MBq/ml raztopina za injiciranje Amyvid 800 MBq/ml raztopina za injiciranje florbetapir (18F)
Amyvid 1900 MBq/mL solution for injection Florbetapir (18F)
Amyvid 1900 MBq/ml raztopina za injiciranje florbetapir (18F)
Amyvid 1900 MBq/mL: 1 mL of solution for injection contains 1900 MBq of florbetapir (18F) at the date and time of calibration.
Amyvid 1900 MBq/ml: En mililiter raztopine za injiciranje vsebuje 1900 MBq florbetapirja (18F) ob času kalibracije.
Amyvid 800 MBq/mL solution for injection Florbetapir (18F)
Amyvid 800 MBq/ml raztopina za injiciranje florbetapir (18F)
Amyvid 800 MBq/mL: 1 mL of solution for injection contains 800 MBq of florbetapir (18F) at the date and time of calibration.
Amyvid 800 MBq/ml: En mililiter raztopine za injiciranje vsebuje 800 MBq florbetapirja (18F) ob času kalibracije.
Amyvid contains the active substance florbetapir (18F).
Zdravilo Amyvid vsebuje zdravilno učinkovino florbetapir (18F).
Amyvid images should only be interpreted by readers trained in the interpretation of PET images with florbetapir (18F).
Slike z zdravilom Amyvid lahko interpretirajo le odčitovalci, usposobljeni za interpretacijo PET- posnetkov s florbetapirjem (18F).
Amyvid is a clear, colourless solution for injection.
Zdravilo Amyvid je bistra, brezbarvna raztopina za injiciranje.
Amyvid is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment.
Zdravilo Amyvid je radiofarmak, indiciran za slikanje gostote β-amiloidnih nevritičnih leh s pozitronsko emisijsko tomografijo (PET) v možganih odraslih bolnikov s kognitivno motnjo, pri katerih se ugotavlja Alzheimerjeva bolezen (AB) in drugi vzroki kognitivne motnje.
Amyvid is a solution for injection that contains the active substance florbetapir (18F).
Amyvid je raztopina za injiciranje, ki vsebuje zdravilno učinkovino florbetapir (18F).
Amyvid is given as an injection into your vein (intravenous injection) followed by a flush of sodium chloride solution to ensure full delivery of the dose.
Zdravilo Amyvid se daje z injekcijo v veno (intravenska injekcija), ki ji sledi spiranje z raztopino natrijevega klorida, s čimer se zagotovi injiciranje celotnega odmerka.
Amyvid is given to people with memory problems so that doctors can perform a type of brain scan, called a PET scan.
Zdravilo Amyvid se daje bolnikom, ki imajo težave s spominom, da zdravniki lahko opravijo možgansko preiskavo, imenovano PET-preiskava.
Amyvid is not intended for use in children and adolescents.
Zdravilo Amyvid ni namenjeno uporabi pri otrocih in mladostnikih.
Amyvid is supplied in 10 mL or 15 mL clear Type I borosilicate glass vials with FluroTec-coated chlorobutyl elastomeric stoppers and aluminium seals.
Zdravilo Amyvid je na voljo v 10 ml ali 15 ml prozornih vialah iz borosilikatnega stekla tipa I z zamaškom iz klorobutilnega elastomera, prevlečenega s FluroTec®, in aluminijasto zaporko.
An 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9 mg/kg oral dose.
Intravenski odmerek 8 mg/kg povzroči približno 2-krat večjo izpostavljenost vorikonazolu kot peroralni odmerek 9 mg/kg.
An 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9 mg/kg oral dose.
Intravenskiodmerek 8 mg/kg povzroči približno 2-krat večjo izpostavljenost vorikonazolu kot peroralni odmerek 9 mg/kg.
An 80 mg dose of telmisartan administered to healthy volunteers almost completely inhibits the angiotensin II evoked blood pressure increase.
Pri zdravih prostovoljcih odmerek telmisartana po 80 mg skoraj povsem zavre zvišanjekrvnega tlaka, ki ga povzroča angiotenzin II.
an abnormal blood test result for bilirubin, a chemical produced from the normal breakdown of red blood cells
nenormalni rezultati krvnih testov bilirubina, snovi, ki nastaja ob nenormalni razgradnji rdečih krvničk
an abnormal blood test result for creatinine, a chemical excreted in the urine, and a measure of kidney function
nenormalni rezultati krvnih testov kreatinina, snovi, ki se izloča v urin, ter meritev ledvičnih funkcij
An abnormal response by the body’s immune system is thought to play an important part in the process which damages the CNS.
Predvidevajo, da ima nenormalen odziv imunskega sistema telesa pomembno vlogo v procesu, ki uničuje OŽ.
an abnormal tube-like connection or passage between the windpipe and the gullet, between internal organs and skin, between the vagina and any parts of the gut or between other tissues that are not normally connected (fistula), and are judged by your doctor to be severe,
neobičajna povezava ali prehod, podoben cevi, med sapnikom in požiralnikom, med notranjimi organi in kožo, med nožnico in katerim koli delom črevesa ali med drugimi tkivi, ki normalno niso povezani (fistula), in jih vaš zdravnik oceni kot resne,
an abnormal variation of hormones and liver enzyme levels in the blood
nenormalne spremembe v vrednostih hormonov in jetrnih encimov v krvi
an abnormality in your electrocardiogram called atrioventricular block;
nenormalnost v elektrokardiogramu, ki se imenuje atrioventrikularni blok;
an abnormality of red blood cells (sickle cell anaemia)
nepravilnost rdečih krvnih celic (srpastocelično anemijo),
an abnormality of the red blood cells (sickle cell anaemia);
abnormalnost rdečih krvničk (anemijo srpastih celic),
an abnormally high alkalinity of the blood and other body tissues
nenormalno močna bazičnost krvi in drugih telesnih tkiv
An absolute benefit of 13 percentage points in favour of the Herceptin arm was estimated in terms of 3-year event-free survival rate (65 % versus 52 %).
Absolutna korist 13 odstotnih točk v prid skupini, ki je prejemala zdravilo Herceptin, je bila ocenjena v smislu 3-letnega preživetja brez bolezni (65 % proti 52 %).
An accelerated elimination procedure can be used at any time after discontinuation of teriflunomide (see section 4.6 and 5.2 for procedural details).
Postopek pospešenega izločanja se lahko izvede kadar koli po prekinitvi jemanja teriflunomida (za podrobnosti postopka glejte poglavji 4.6 in 5.2).
An action plan together with timelines for addressing the issues that need to be resolved before the authorisation can revert to normal status will also be submitted.
Družba bo predložila tudi akcijski načrt, skupaj s časovnimi okviri glede obravnavanja vprašanj, ki jih je še treba razrešiti, da bo dovoljenje za promet dobilo normalen status.